Scientific Programme
Click on the button below to download the final programme:
FINAL PROGRAMME
The lecture hall “Jesuitensaal” is located on the second floor of the conference venue.
| PRE-MEETING SYMPOSIA | ||
| SYMPOSIUM ON MALIGNANT SKIN INFLAMMATION | ||
| 8.00AM-8.10AM | Welcome address | Organizing committee |
| MALIGNANT INFLAMMATION – ROLE OF INFECTIONS AND ENVIRONMENTAL DRIVERS | ||
| 8.10AM-8.30AM | Keynote lecture: Bacteria fuel malignant inflammation and disease activity in CTCL | Niels Ødum, Copenhagen, Denmark |
| 8.30AM-8.50AM | Microbial triggers and clonal evolution in CTCL pathogenesis | Sergei Koralov, New York, NY, USA |
| 8.50AM-9.10AM | Chronic T cell activation by CD1a and Staphylococcal lipids | Annemieke de Jong, New York, NY, USA |
| 9.10AM-9.30AM | AhR signaling drives defective type I IFN signaling in mycosis fungoides | Rachael Clark, Boston, MA, USA |
| 9.30AM-9.50AM | Infectious and environmental drivers of CTCL | Larisa Geskin, New York, NY, USA |
| 10.00AM-10.30AM | COFFEE BREAK | |
| ROLE OF THE MICROENVIRONMENT | ||
| 10.30AM-10.50AM | The micromilieu in CTCL: From inflammation over tumor progress to antitumoral response | Gabor Dobos, Berlin, Germany |
| 10.50AM-11.10AM | Targeting immunosuppressive macrophages in the tumor microenvironment of CTCL | Christiane Querfeld, Duarte, CA, USA |
| 11.10AM-11.30AM | The role of cancer-associated fibroblasts in MF | Emmilia Hodak, Tel Aviv, Israel |
| 11.30AM-11.50PM | ADCC in lymphoma treatment – A spotlight on NK cells? | Emmanuella Guenova, Lausanne, Switzerland |
| 12.00PM-1.00PM | SPONSORED LUNCH SYMPOSIUM | More information |
| PATHOGENESIS AND ITS TRANSLATION | ||
| 1.00PM-1.20PM | Towards a better understanding of the CTCL cellular and molecular landscape | Muzlifah Haniffa, Newcastle, UK |
| 1.20PM-1.40PM | Insights into pathogenesis and translational strategies for CTCL | Michael Girardi, New Haven, CT, USA |
| 1.40PM-2.00PM | An individualized approach to therapy of advanced MF in the era of personalized medicine | Oleg Akilov, Pittsburgh, PA, USA |
| 2.00AM-2.20AM | Indolent vs. aggressive disease | Patrick M. Brunner, New York, NY, USA |
| 2.20AM-2.40AM | COFFEE BREAK | |
| PATHOGENESIS BASED TREATMENT STRATEGIES | ||
| 2.40PM-3.00PM | CTCL: unraveling the mechanisms of long-term disease control | Adèle de Masson, Paris, France |
| 3.00PM-3.20PM | New treatment targets | Martine Bagot, Paris, France |
| 3.20PM-3.40PM | Therapeutic mechanisms in CTCL: Lessons learnt from photo(chemo)therapy | Peter Wolf, Graz, Austria |
| 3.40PM-4.00PM | The association of CTCL with inflammatory skin disorders and its treatments - True causality or misdiagnosis? | Shamir Geller, New York, NY, USA |
| 4.00PM-4.15PM | Concluding remarks and awards | |
| 01.00PM - 04.00PM | Pre-Meeting Symposium: Research Techniques in Atopic Dermatitis (Registration via IEC website required) | International Eczema Council |
| ISDS 2023 CONFERENCE OPENING | ||
| 04.30PM - 04.40PM | Welcome Address Welcome Words from the president of the Austrian Academy of Sciences | Organizing Committee Heinz Faßmann |
| 04.40PM -05.00PM | Setting the Stage | Georg Stingl, Vienna, Austria |
| 05.00PM - 05.30PM | Keynote lecture “Immune system-driven skin fibrosis” | Richard Flavell, New Haven, CT, USA |
| 05.30PM - 06.00PM | Type 2 immunity across diseases | Bart Lambrecht, Ghent, Belgium |
| 06.00PM - 07.00PM | Oral presentations from selected abstracts Spatial proteomic and transcriptomic profiling of lichen planus reveals a unique inflammatory architecture Matthew Vesely, New Haven, USA Targeting the IL-15 signaling pathway prevents the formation of cutaneous TRM and limits flare-ups of allergic contact dermatitis Roxane Cuzin, Lyon, France Effectivity of mTOR inhibition in cutaneous sarcoidosis Anna Redl, Vienna, Austria Bidirectional TGF-beta signaling between CD8+ T cells and melanocytes determines melanocyte death in vitiligo, rescued by small-molecule receptor blocker Shany Sherman, Worcester, USA The Phase 2 MIRA trial of the IL-17A- and IL-17F-inhibiting Nanobody® sonelokimab in patients with active, moderate-to-severe hidradenitis suppurativa (HS): Week 12 results Brian Kirby, Dublin, Ireland | |
| 07.00PM - 10.00PM | Reception and poster viewing | More information |
| 08.00 AM – 09.30 AM | Sponsored Breakfast Symposium | More information |
| 09.30 AM – 09.45 AM | BREAK | |
| 09.45 AM – 10.15 AM | Innate immunity in the skin | Michel Gilliet, Lausanne, Switzerland |
| 10.15 AM – 10.45 AM | The microbiome in inflammatory skin diseases | Heidi Kong, Bethesda, MD, USA |
| 10.45 AM – 11.15 AM | Developing a human skin cell atlas | Muzlifah Haniffa, Newcastle, United Kingdom |
| 11.15 AM – 11.45 AM | Oral presentations from selected abstracts Skin CD69+CD62L+ TRM, a subset with renewal capacity gives rise to CD103+CD49a+ TRM Wenning Zheng, Copenhagen, Denmark IL-9 sensitizes human pathogenic Th2 cells to pro-inflammatory IL-18 signals in atopic dermatitis Stefanie Schärli, Bern, Switzerland | |
| 11.45 AM – 12.00 PM | BREAK | |
| 12.00 PM – 01.30 PM | Sponsored Lunch Symposium | More information |
| 01.30 PM – 01.45 PM | BREAK | |
| 01.45 PM – 02.15 PM | Mitochondrial ROS and cytoplasmic nucleic acid sensing set the inflammatory tone in human skin | Rachael Clark, Boston, MA, USA |
| 02.15 PM – 02.45 PM | Cutaneous T cell compartments in health and immunodeficiency | Georg Stary, Vienna, Austria |
| 02.45 PM – 03.15 PM | Chronic inflammation – what we learn from cutaneous lymphomas | Patrick M. Brunner, New York, NY, USA |
| 03.15 PM – 03.45 PM | Oral presentations from selected abstracts Squamous Cell Carcinoma in patients with Recessive Dystrophic Epidermolysis Bullosa is associated with dysregulated T cell function Iris K. Gratz, Salzburg, Austria Influence of dupilumab on HSV-specific immune response in atopic dermatitis Stephan Traidl, Hannover, Germany | |
| 03.45 PM – 04.15 PM | COFFEE BREAK | |
| 04.15 PM – 04.45 PM | Dissecting the role of IL-13 in health and disease | Johannes U. Mayer, Marburg, Germany |
| 04.45 PM – 05.15 PM | Janus kinases in inflammation | Massimo Gadina, Bethedsa, MD, USA |
| 05.15 PM – 05.45 PM | Psoriasis | Johann Gudjonsson, Ann Arbor, MI, USA |
| 05.45 PM – 06.15 PM | Newly identification of a CXCR6+ pathogenic skin-resident CD4+ T cell subset in a mouse model of allergic dermatitis that requires CXCL16 for its maintenance | Kenji Kabashima, Kyoto, Japan |
| 07.30 PM - 11.00PM | Conference Networking Event Bus transfer: 06.45pm & 07.15pm at Weiskirchnerstraße 3, 1010 Vienna (between MAK & the Stadtpark) | More information |
| 08.00 AM – 09.30 AM | Oral presentations from selected abstracts AhR agonism by tapinarof regulates TH2 and TH17 cell function in human skin Fabian Luther, Bern, Switzerland Effect of Ruxolitinib Cream on Biomarkers of Atopic Dermatitis Susan Smith, Wilmington, USA Treatment with the oral CCR4 antagonist RPT193 results in meaningful changes in cutaneous biomarkers detected by transcriptomic profiling of tape strips Ester Del Duca, New York, USA Spesolimab Use in Treatment of Severe Pyoderma Gangrenosum Sophie Guenin, New York, USA Efficacy and safety of amlitelimab (an anti-OX40 ligand antibody) in patients with moderate-to-severe atopic dermatitis (AD): 24-week results from a Phase 2b trial (STREAM-AD) Wendell Valdecantos, Cambridge, USA EVO756 is a novel MRGPRX2 antagonist that potently inhibits human mast cell degranulation in response to multiple agonists – potential treatment for CSU and beyond Hans E Hofland, Palo Alto, USA Lebrikizumab reduces systemic inflammation in serum of patients with moderate-to-severe atopic dermatitis Emma Guttman-Yassky, New York, NY, USA | |
| 09.30 AM – 09.45 AM | BREAK | |
| 09.45 AM – 10.15 AM | Neuronal immunology interactions | Dan Kaplan, Pittsburgh, PA, USA |
| 10.15 AM – 10.45 AM | Itch and neuroinflammation | Brian Kim, New York, NY, USA |
| 10:45 PM– 11:15 AM | "Of mice and men” - A Tale of Inflammatory Skin Diseases | Nicole Ward, Nashville, TN, USA |
| 11:15 AM – 11.45 AM | Oral presentations from selected abstracts Human epidermal Langerhans cells emigrate and induce a tolerogenic immune response in response to tick feeding and tick-borne pathogens Lisa Kleissl, Vienna, Austria Detection of skin allergy biomarkers for point-of-care diagnosis of contact dermatitis Marine-Alexia Lefevre, Bron, France | |
| 11.45 PM – 12.00 PM | BREAK | |
| 12.00 PM – 01.30 PM | Sponsored Lunch Symposium | More information |
| 01.30 PM – 01.45 PM | BREAK | |
| 01.45 PM – 02.15 PM | Advances in atopic dermatitis | Alan Irvine, Dublin, Ireland |
| 02.15 PM – 02.45 PM | Alopecia areata | Ralf Paus, Miami, FL, USA |
| 02.45 PM – 03.15 PM | Atopic dermatitis & alopecia areata: Common mechanisms and targets | Emma Guttman, New York, NY, USA |
| 03.15 PM – 03.45 PM | Oral presentations from selected abstracts Effectiveness of OR-101, a Next Generation Highly Selective JAK3 Inhibitor, in a Humanized Murine Model of Alopecia Areata Marta Bertolini, Münster, Germany Non-lesional type 2 and type 17/22 immune activation precedes lesional type 1-associated inflammation in skin of vitiligo patients Patrick M. Brunner, New York, USA | |
| 03.45 PM – 04.15 PM | COFFEE BREAK | |
| 04.15 PM – 04.45 PM | Oral presentations from selected abstracts Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells Christine Bangert, Vienna, Austria Tape strips detect molecular alterations and cutaneous biomarkers in hidradenitis suppurativa skin Kristina Navrazhina, New York, USA | |
| 04.45 PM – 05.15 PM | Hidradenitis suppurativa | James G. Krueger, New York, NY, USA |
| 05.15 PM – 05.45 PM | Emerging opportunities in vitiligo | John Harris, Worcester, MA, USA |
| 05.45 PM – 06.45 PM | Oral presentations from selected abstracts Immune-mesenchymal crosstalk contribute to the expansion of autoreactive plasma cells in the tertiary lymphoid structures in Hidradenitis Suppurativa Catherine Lu, New York, USA Tape Strip Genomic Profiling of Lesional and -lesional Atopic Dermatitis Skin Identifies Early and Progressive Normalization Following Treatment With Abrocitinib Madeline Kim, New York, USA Deciphering dysfunctional regultory T cells in atopic dermatitis Hyun Je Kim, Seoul, South Korea Efficacy, Safety, and Tolerability of GSK1070806, an Anti–IL-18 Monoclonal Antibody, in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study John Kelly, Collegeville, USA | |
| 06.45 PM - 07.00 PM | BREAK | |
| 07.00 PM - 8.30 PM | Sponsored Dinner Symposium | More information |
| 08.00 AM - 9.30 AM | Oral presentations from selected abstracts Single cell transcriptome revealed the role of CCL19+ inflammatory epithelial cells in pemphigus Yiyi Wang, Chengdu, China Chronic hand eczema shares a common molecular signature regardless of atopic dermatitis status Jonathan Bar, New York, USA Cutaneous lupus single cell analyses reveal critical type I interferon mediated reprogramming of skin stroma Jeff Gehlhausen, New Haven, USA Preclinical Ex Vivo and In Vivo Evidence Supporting Selective Inhibition of Tyrosine Kinase 2-Dependent, IL-12-Mediated Signaling as a Novel Pharmacological Strategy for Alopecia Areata Management Ian M. Catlett, Princeton Pike, USA A Chronic Inflammatory Environment Revealed In Age Spots From Both European And Asian Volunteers Constance Alvarez-Duchesne, Aulnay-Sous-Bois, France Clinical response to IL-22RA1 blockade is associated with reduction of systemic inflammation Britta Martel, Ballerup, Denmark | |
| 09.30 AM – 09.45 AM | BREAK | |
| 9.45 AM – 10.15 AM | Academic / industry collaboration and perspectives | Kristian Reich, Hamburg-Eppendorf, Germany |
| 10.15 AM – 10.45 AM | The Past, Present, and Future of Cell Therapies for Autoimmunity | Aimee Payne, Philadelphia, PA, USA |
| 10.45 AM – 11.15 AM | Lupus: New Developments | Joseph Merola, Boston MA, USA |
| 11.15 AM – 11.45 AM | The role of the target tissue in skin autoimmunity: pemphigus as a case study | Eli Sprecher, Tel Aviv, Israel |
| 11.45 PM – 12.00 PM | Oral presentations from selected abstracts Scarring alopecia is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege Karoline Strobl, Vienna, Austria | |
| 12.00 PM – 12.15 PM | BREAK | |
| 12.15 PM – 01.45 PM | Sponsored Lunch Symposium | More information |
| 01.45 PM – 02.00 PM | BREAK | |
| 02.00 PM – 02.30 PM | Artificial Intelligence in Dermatology | Philipp Tschandl, Vienna, Austria |
| 02.30 PM – 03.00 PM | Urticaria | Marcus Maurer, Berlin, Germany |
| 03.00 PM | Award Ceremony & Conference Closing | |
| 03.30 PM - 06.30 PM | Industry Satellite Event | More information |